Table 3.
Reported pulmonary manifestations in immunocompromised patientsa
| Reference(s) | Age of patient (yr)/sex | Country | Underlying disease(s) | Initial presentation(s) | Culture source(s) | Treatment | Outcome |
|---|---|---|---|---|---|---|---|
| 137 | 72/F | The Netherlands | RA/OSAS | Pneumonia | Sputum | R, AZI | Resolution |
| 126 | 32/M | United States | BMT, MDS | Pulmonary infiltrate | Blood | None | Death |
| 157 | 62/F | United States | NA | Pulmonary nodule | Lung biopsy specimen | R, E | Cure |
| 123 | 30/F | United States | Renal transplant, subsequent AIDS | Skin lesions, septic arthritis, subsequent pulmonary involvement | NA | E, I, R, subsequent Min | Initial resolution, subsequent death |
| 135 | 51/M | United States | AIDS | Bronchitis | Sputum, bone | CI, D, E, I, P, R | Resolution |
| 76 | 42/M | United States | BMT, MDS | Pulmonary infiltrate | BAL fluid, sputum | R, E, CI, CLR, AK, P | Death |
| 76 | 37/M | United States | AIDS | Skin lesions, pneumonia | Skin, sputum | AK, CI, D, E, I, R | Responded and then relapsed and died |
| 27, 75, 76, 135 | 35/M | United States | AIDS | Skin, pulmonary infiltrate | Skin, sputum | R, E, CI, AK, D, Ery | Death |
| 27, 75, 76, 135, 156 | 27/M | United States | BMT, AA | Pulmonary nodules | Sputum, BAL fluid, lung biopsy specimen | R, E, AK, P, I, S | Death |
a
I, isoniazid; R, rifampin; RB, rifabutin; E, ethambutol; CI, ciprofloxacin; AK, amikacin; AZI, azithromycin; CLR, clarithromycin; P, pyrazinamide; D, doxycycline; Min, minocycline; Ery, erythromycin; S, streptomycin; RA, rheumatoid arthritis; BMT, allogeneic bone marrow transplantation; MDS, myelodysplastic syndrome; AA, aplastic anemia; CML, chronic myelogenous leukemia; BAL, bronchoalveolar lavage; OSAS, obstructive sleep apnea syndrome; NA, data not available.